Address to: Commissioner for Patents

Box Patent Application Washington, DC 20231

UTILITY PATENT APPLICATION TRANSMITTAL AND FEE SHEET

Transmitted herewith for filing under 37 CFR §1.53(b) is the utility patent application of

Applicant (or identifier): PAUL L. HALLENBECK

EL 835204315 US

Express Mail Label Number

NEERAJA IDAMAKANTI JOHN L. JAKUBCZAK MICHAEL KALEKO

MICHELE LYNETTE ROLLENCE

THEODORE SMITH

SUSTAN C. STEVENSON DAVID A. STEWART

Title:

ADENOVIRUS PARTICLES WITH MUTAGENIZED FIBER

PROTEINS

Before calculating the filing fee, please cancel claims

Enclosed are:

1. 2. 3. 4. 5. 6. 7. 8. 9. 10. 11.		Specification (Including Claims and Abstract) - 43 pages Drawings - 17 sheets Executed Declaration and Power of Attorney (original or copy) Microfiche Computer Program (appendix) Nucleotide and/or Amino Acid Sequence Submission Computer Readable Copy Paper Copy Statement Verifying Identity of Above Copies Preliminary Amendment Assignment Papers (Cover Sheet & Document(s)) English Translation of Information Disclosure Statement Certified Copy of Priority Document(s) Return Receipt Postcard Other: Unexecuted Declaration and Power of Attorney; Patent Application Bibliographic Data Sheet
Filing	g fee	calculation:
	Befo	ore calculating the filing fee, please enter the enclosed Preliminary Amendment.

OSEZOÇOZ OSEOCI

Basic Filing Fee									\$	710
Multiple Dependent Claim Fee (\$ 270)										270
Foreign l	Language Surchar	ge (\$ 130)	_						\$	
-	For	Number Filed		Number Extra			Rate			
Extra Claims	Total Claims	85	-20	65	×	\$	18	=	\$	1,170
	Independent Claims	2	-3	0	×	\$	80	=======================================	\$	
-					то	TAL	FILING	FEE	\$	2,150

Please charge Deposit Account No. 19-0134 in the name of Novartis Corporation in the amount of \$2,150. An additional copy of this paper is enclosed. The Commissioner is hereby authorized to charge any additional fees under 37 CFR §1.16 and §1.17 which may be required in connection with this application, or credit any overpayment, to Deposit Account No. 19-0134 in the name of Novartis Corporation.

Please address all correspondence to the address associated with Customer No. 001095, which is currently:

Thomas Hoxie
Novartis Corporation
Patent and Trademark Dept.
564 Morris Avenue
Summit, NJ 07901-1027

Date: May 30, 2001

Please direct all telephone calls to the undersigned at the number given below, and all telefaxes to (301) 258-4620.

Respectfully submitted,

Geoffrey M. Karny

Attorney for Applicants

Reg. No. 31,382

Tel. No. (301) 258-4640

	Docket Number 4-31452A
FILING BY "EXF	PRESS MAIL" UNDER 37 CFR 1.10
EL 835204315 US Express Mail Label Number	May 30, 2001 Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

HALLENBECK ET AL.

APPLICATION NO: TO BE ASSIGNED

FILED: MAY 30, 2001

FOR: ADENOVIRUS PARTICLES WITH MUTAGENIZED FIBER

PROTEINS

Commissioner for Patents Washington, D.C. 20231

SUBMISSION OF SEQUENCE LISTING INCLUDING STATEMENT OF VERIFICATION

Sir:

Applicants hereby provide a Computer Readable Form of the Sequence Listing as well as the Paper Copy thereof. The undersigned states that the Paper Copy and the Computer Readable Form, submitted in accordance with 37 CFR §1.821(c) and (e), respectively, are the same.

Respectfully submitted,

Novartis Corporation Patent and Trademark Dept. 564 Morris Avenue Summit, NJ 07901-1027

Date: May 30, 2001

Geofffey M. Karny Attorney for Applicants Reg. No. 31,382 (301) 258-4640